title: [Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases amd review of the literature].
abstract: OBJECTIVE
  In medical literature, primary pulmonary hypertension occurs in 0.5% of human immunodeficiency virus (HIV)-infected patients, irrespective of the stage of the HIV disease, and is more frequent in drug users. Plexogenic arteriopathy is the most frequent histological lesion.
  
  
  METHODS
  We retrospectively report on nine cases of primary pulmonary hypertension during HIV infection.
  
  
  RESULTS
  The subjects were four women and five men, mean age 38 years old. Four of them had been sexually contaminated and five had contracted the disease through intravenous drug use. At the time primary pulmonary hypertension was diagnosed, mean CD4 cell count was 234 +/- 217/mm3 and the viral load was low or undetectable. Primary pulmonary hypertension has been diagnosed an average of 7 months after the first cardiovascular clinical signs had started. Despite anti-coagulant (7/9 cases), vasodilatator (4/9 cases) and/or diuretic (7/9 cases) therapy, the progression of the disease quickly turned out to be negative (seven deaths).
  
  
  CONCLUSIONS
  Diagnosis of primary pulmonary hypertension should be considered when unexplained dyspnea occurs in an HIV-positive patient. At initial evaluation, alterations of hemodynamic parameters are usually less severe than during idiopathic primary pulmonary hypertension, but their progression is quicker and more severe, independent of the patient's immune status. Current data do not allow the determination of whether antiretroviral therapy is active in primary pulmonary hypertension evolution. Therapeutic evaluation with prostacyclin is currently being carried out. While the life expectancy of HIV-infected patients extends, primary pulmonary hypertension occurrence could increase and call for early diagnosis, thus allowing for specific care.
authors.affiliation: Service d'immunologie clinique, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75908 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Le Houssine
authors.forename: M
authors.initials: M
authors.lastname: Karmochkine
authors.forename: F
authors.initials: F
authors.lastname: Ledru
authors.forename: D
authors.initials: D
authors.lastname: Batisse
authors.forename: C
authors.initials: C
authors.lastname: Piketty
authors.forename: M D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: L
authors.initials: L
authors.lastname: Weiss
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents